Since 2000, malaria mortality rates have fallen by 66% among all ages groups and by 71% among children under five in Africa. The massive drop is a testament to the hard work of malaria prevention workers, but there is still much work to be done to rid the world of the disease. A new vaccine developed by a U.S-based team could do just that. The vaccine uses a genetically modified version of the parasite that exposes the immune system to the disease without allowing it to develop into full-blown malaria. In initial tests, the vaccine stimulated a response that could block an actual infection without any significant side-effects. The results are promising and has warranted further clinical testing.